Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Halozyme Therapeutics Inc. buy Benchmark Co.

Start price
€36.23
16.04.24 / 50%
Target price
€46.98
16.04.25
Performance (%)
-0.55%
Price
€36.53
24.04.24
Summary
This prediction is currently active. Since the start of the prediction for Halozyme Therapeutics Inc. the price has only changed by -0.55%. This prediction currently runs until 16.04.25. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this prediction
Performance without dividends (%)
Name 1w
Halozyme Therapeutics Inc. 0.717%
iShares Core DAX® 2.594%
iShares Nasdaq 100 3.553%
iShares Nikkei 225® 0.687%
iShares S&P 500 2.209%

Comments by Benchmark_Co_ for this prediction

In the thread Halozyme Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -0.55%
Target price 46.975
Change
Ends at 16.04.25

Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat

Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€31.35
19.01.24
€45.94
19.01.25
16.52%
24.04.24

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€33.23
20.10.23
€47.17
20.10.24
9.93%
24.04.24